



CENTER FOR PATHOPHYSIOLOGY,
INFECTIOLOGY AND IMMUNOLOGY
MEDICAL UNIVERSITY OF VIENNA

COLLOQUIUM IN PATHOPHYSIOLOGY, INFECTIOLOGY AND IMMUNOLOGY

Michael Hudecek, MD

***Julius Maximilians University Medical School
Hematology/Oncology Division
Würzburg, Germany***

“Can Cancer Be Cured with a Bag of T Cells?”

Novel Targets and Technologies for CAR T”

host: Johannes Huppa

***Where: Lecture Hall 2,
Institute for Hygiene,
Kinderspitalgasse 15, 1090 Vienna***

When: Thursday, May 3rd 2018, 10 am



Biosketch

Michael Hudecek, MD



- **Dr. Michael Hudecek** studied medicine at Leipzig University, where he focused his doctoral thesis work under the supervision of Dieter Niederwieser on the role of the minor histocompatibility antigen HA1 in graft versus leukemia reaction. For his postdoctoral studies he joined the laboratory of Stanley Riddell at the Fred Hutchinson Cancer Research Center in Seattle, USA, where he engineered tumor-reactive Chimeric Antigen Receptor (CAR) T cells for adoptive immunotherapy. He returned in 2012 to Germany as a resident physician to start his own laboratory at the Julius Maximilians University Medical School in Würzburg. Dr. Hudecek's research interest encompass (1) the identification of tumor-associated antigens, (2) the engineering of tumor-specific CAR T cells and (3) adoptive immunotherapy with the use of CAR-T cells, tumor-specific T cells and antibodies. He is a member of the Bavarian Academy of Sciences and a recipient of the m4-award of the Free State of Bavaria and Artur-Pappenheim Award of the German Society for Hematology and Medical Oncology.

Recent publications

- Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, **Hudecek M** (2018) CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. **Leukemia** doi: 10.1038/s41375-018-0009-0. [Epub ahead of print] PMID: 29472720
- Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, Einsele H, **Hudecek M** (2017) SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. **Blood** 130(26):2838-2847. doi: 10.1182/blood-2017-04-778423. Epub 2017 Oct 31. PMID: 29089311
- García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, **Hudecek M** (2017) Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab **Blood** 129(25):3386-3388. doi: 10.1182/blood-2017-03-770776 PMID: 28476749
- Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, Ivics Z, **Hudecek M** (2016). Enhanced Engineering of Chimeric Antigen Receptor (CAR)-Modified T Cells at Genomic Safe Harbor Loci Using Non-Viral Sleeping Beauty-Mediated Transposition From Minicircle Vectors. **Leukemia** doi: 10.1038/leu.2016.180.